Patents by Inventor Thérèse Di Paolo

Thérèse Di Paolo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20210338621
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 11096916
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Novartis AG
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20200108035
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 9, 2020
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 10537539
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: January 21, 2020
    Assignee: NOVARTIS AG
    Inventors: Thérèse Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • ORGANIC COMPOUNDS
    Publication number: 20150272929
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Inventors: Daniel UMBRICHT, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo
  • COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
    Publication number: 20140228398
    Abstract: The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Therese Di Paolo, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donal Johns
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20140171448
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of a Movement Disorder selected from Dystonia, Dyskinesia, Chorea, Restless Legs Syndrome, Tics, Tremor, Myoclonus, Startle, Stiff Person Syndrome, Gait Disorder, Parkinson's Disease and Symptomatic Parkinsonism.
    Type: Application
    Filed: January 20, 2012
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donald Johns, Thérése Di Paolo
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20120172346
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 5, 2012
    Inventors: Thérèse Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • ORGANIC COMPOUNDS
    Publication number: 20100249136
    Abstract: The invention concerns the use an mGluR modulator, e.g.
    Type: Application
    Filed: October 9, 2008
    Publication date: September 30, 2010
    Inventors: Daniel Umbricht, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo
  • Combined therapy for the treatment of parkinson's disease
    Patent number: 7576073
    Abstract: The present invention concerns a method and a pharmaceutical composition for treating the symptoms associated to Parkinson's disease. The method and the pharmaceutical composition use a combination of a therapeutically effective amount of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor, such as levodopa. The present invention also concerns to the use of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor to manufacture a medicament for treating a neurodegenerative diseases.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: August 18, 2009
    Assignee: Université Laval
    Inventor: Thérèse Di Paolo
  • Combined therapy for the treatment of Parkinson's disease
    Publication number: 20050267085
    Abstract: The present invention concerns a method and a pharmaceutical composition for treating the symptoms associated to Parkinson's disease. The method and the pharmaceutical composition use a combination of a therapeutically effective amount of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor, such as levodopa. The present invention also concerns to the use of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor to manufacture a medicament for treating a neurodegenerative diseases.
    Type: Application
    Filed: May 28, 2004
    Publication date: December 1, 2005
    Applicant: UNIVERSITE LAVAL
    Inventor: Therese Di Paolo